Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines.

Oncotarget - 14 Jun 2016

Kobayashi Susumu S, Vali Shireen, Kumar Ansu, Singh Neeraj, Abbasi Taher, Sayeski Peter P

Abstract excerpt

Previous studies have shown that the bone marrow micro-environment supports the myeloproliferative neoplasms (MPN) phenotype including via the production of cytokines that can induce resistance to frontline MPN therapies. However, the mechanisms by which this occurs are poorly understood. Moreover, the ability to rapidly identify drug agents that can act as adjuvants to existing MPN frontline therapies is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Screening Assays, Antitumor
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-6

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Proto-Oncogene Proteins c-bcl-2

Share to Tumor Microenvironment

Share to Tumor Necrosis Factor-alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 27056884
DOI: 10.18632/oncotarget.8540
PMCID: PMC5094977

Genes

SET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines.PMID 27056884Read ↗

Patient-tailored design of AML cell subpopulation-selective drug combinationsSemantic proximity Read ↗

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.Semantic proximity Read ↗

A Scalable, Open-Source Implementation of a Large-Scale Mechanistic Model for Single Cell Proliferation and Death SignalingSemantic proximity Read ↗

Unlocking the Potential of Therapy-Induced Cytokine Responses: Illuminating New Pathways in Cancer Precision MedicineSemantic proximity Read ↗

Experimental therapeutics for patients with myeloproliferative neoplasias.Semantic proximity Read ↗

Multimodal gene and targeted drug therapy for chronic myelogenous leukemia: Computational target analysis and therapeutic validationSemantic proximity Read ↗

How I treat Philadelphia chromosome–positive acute lymphoblastic leukemiaSemantic proximity Read ↗

Mathematical Modeling of MPNs Offers Understanding and Decision Support for Personalized TreatmentSemantic proximity Read ↗

Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasmsSemantic proximity Read ↗

Combinatorial drug-microenvironment interaction mapping reveals cell-extrinsic drug resistance mechanisms and clinically relevant patient subgroups in CLLSemantic proximity Read ↗

Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing dataSemantic proximity Read ↗

Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.